Sound Pharmaceuticals researchers are quickly moving forward on developing neuroceuticals to stem hearing loss. Hearing loss is the third leading chronic disorder and exceeds the number of persons with either diabetes or visual loss combined.

"According to the NIH, CDC and NIOSH, hearing loss is the most common neurosensory disorder and the most common occupational disease. Hearing loss is found in all age groups and can seriously compromise the quality of life or job performance of those affected.

Hair cell regeneration to improve or restore hearing in persons with permanent hearing loss is a significant product pipeline for Sound Pharmaceuticals, Inc. SPI previously announced that its patent, Method for the treatment of diseases or disorders of the inner ear, was issued in Europe, effective Oct. 1, 2003."

(disclaimer: Eric Lynch, VP of Research, is my brother).